|
Key figures – 1st quarter 2010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR million |
Pharma- ceuticals |
Chemicals |
Corporate and Other |
Total |
Change |
|
Total revenues |
1,514.4 |
584.5 |
– |
2,098.9 |
12.9 |
|
Gross margin |
1,259.4 |
352.9 |
– |
1,612.2 |
15.0 |
|
Research and development |
–309.3 |
–38.1 |
0.1 |
–347.2 |
11.0 |
|
Operating result |
179.5 |
166.7 |
–51.5 |
294.8 |
48.8 |
|
Exceptional items |
– |
– |
– |
– |
– |
|
Earnings before interest and tax (EBIT) |
179.5 |
166.7 |
–51.5 |
294.8 |
127.9 |
|
EBIT before depreciation and amortization (EBITDA) |
381.3 |
210.7 |
–50.9 |
541.1 |
53.4 |
|
Return on sales in % |
11.9 |
28.5 |
– |
14.0 |
|
|
Free cash flow |
188.9 |
126.3 |
–120.4 |
194.8 |
18.8 |
|
Underlying free cash flow |
188.9 |
126.3 |
–108.6 |
206.6 |
26.0 |
|
Underlying free cash flow on revenues |
12.5 |
21.6 |
– |
9.8 |
|
